The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. Women are more likely to have IBS-D than man and is more common in women under 50 years of age.

The potential benefits to participants would be study-related medical care at no-cost and knowledge gained about their condition. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.

To qualify for the study, you must be:

  • Male or female adult 19 years of age or older
  • Have a body mass index (BMI) between 18-40
  • Meet Rome IV Criteria for IBS-D by subject self-report of recurrent abdominal pain that is
    associated with ≥ 2 of the following over the last ≥ 6 months, with frequency of at least 1 day
    per week over the last 3 months (on average) before enrollment:
    a. Related to defecation;
    b. Associated with a change in frequency of stool; and/or
    c. Associated with a change in form (appearance of stool).
  • Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.